Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 9:41 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 649–672 of 5,198 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Thoracic Neoplasm Clear all
Recruiting No phase listed Observational

Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform

NCT06349642
View directory record Official record
Conditions
Early Stage Triple-Negative Breast Carcinoma, Metastatic Bladder Urothelial Carcinoma, Metastatic Cervical Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Metastatic Colorectal Carcinoma, Metastatic Endometrial Carcinoma, Metastatic Esophageal Carcinoma, Metastatic Liver Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Skin Neoplasm, Metastatic Malignant Solid Neoplasm, Resectable Lung Non-Small Cell Carcinoma, Early Stage Lung Non-Small Cell Carcinoma, Resectable Malignant Solid Neoplasm, Resectable Triple-Negative Breast Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Cervical Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8, Recurrent Cervical Carcinoma, Recurrent Colorectal Carcinoma, Recurrent Endometrial Carcinoma, Recurrent Esophageal Carcinoma, Recurrent Liver Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Recurrent Malignant Skin Neoplasm, Recurrent Malignant Solid Neoplasm
Interventions
Biospecimen Collection, Tissue Collection
Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
324 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
3
States / cities
Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Oct 25, 2026, 9:41 AM EDT
Recruiting Phase 2 Interventional

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)

NCT06116682
View directory record Official record
Conditions
Lung Non-Small Cell Carcinoma
Interventions
Amivantamab, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging
Biological · Procedure
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
271
States / cities
Jonesboro, Arkansas • Little Rock, Arkansas • Auburn, California + 229 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 25, 2026, 9:41 AM EDT
Completed Not applicable Interventional Results available

Individualized Lung Tumor Stereotactic Ablative Radiotherapy (iSABR)

NCT01463423
View directory record Official record
Conditions
Non-small Cell Lung Cancer (NSCLC)
Interventions
iSABR, 25 Gray in 1 fraction for small peripheral tumors, iSABR, 50 Gray in 4 fractions for medium peripheral tumors, iSABR, 54 Gray in 3 fractions for large peripheral tumors, iSABR, 40 Gray in 4 fractions for small central tumors, iSABR, 50 Gray in 4 fractions for medium central tumors, iSABR, 60 Gray in 8 fractions for large central tumors
Radiation
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
256 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2022
U.S. locations
2
States / cities
Stanford, California • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 19, 2024 · Synced Oct 25, 2026, 9:41 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Pilot Study of Biopsy Scanner for Evaluation of Bronchoscopic Small Biopsy Specimens to Determine Adequacy

NCT05393154
View directory record Official record
Conditions
Lung Cancer
Interventions
Biopsy Adequacy Evaluation by Aquyre Biopsy Scanner
Device
Lead sponsor
Aquyre Bioscience, Inc
Industry
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 25, 2026, 9:41 AM EDT
Completed Phase 2 Interventional Results available

Avastin/Docetaxel/Carboplatin in Non-Small Cell Lung Cancer

NCT00271505
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Bevacizumab (Avastin), Carboplatin, Docetaxel
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2017
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 11, 2020 · Synced Oct 25, 2026, 9:41 AM EDT
Terminated Phase 2 Interventional

Safety and Efficacy Study of Glufosfamide in Patients With Recurrent Sensitive Small Cell Lung Carcinoma

NCT00435578
View directory record Official record
Conditions
Carcinoma, Small Cell Lung
Interventions
Glufosfamide
Drug
Lead sponsor
Threshold Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
3
States / cities
Greenbrae, California • Tampa, Florida • Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 30, 2009 · Synced Oct 25, 2026, 9:41 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Validation of a Multi-gene Test for Lung Cancer Risk

NCT01130285
View directory record Official record
Conditions
Lung Cancer
Interventions
Lung Cancer Risk Test
Genetic
Lead sponsor
University of Toledo Health Science Campus
Other
Eligibility
50 Years to 90 Years
Enrollment
403 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2026
U.S. locations
13
States / cities
Denver, Colorado • Ann Arbor, Michigan • Detroit, Michigan + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2025 · Synced Oct 25, 2026, 9:41 AM EDT
Active, not recruiting Not applicable Interventional

Comparison of Imaging Characteristics of uEXPLORER and Conventional PET/CT in Patients With Lung Cancer, Lymphoma, and Melanoma

NCT04478318
View directory record Official record
Conditions
Lung Neoplasm, Lymphoma, Melanoma, Fluorodeoxyglucose, Positron-emission Tomography
Interventions
uEXPLORER/mCT, mCT/uEXPLORER
Device
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 25, 2026, 9:41 AM EDT
Completed Phase 2 Interventional Results available

Multimodality Treatment for Patients With Resectable Non-Small Cell Lung Cancer (NSCLC) - BEACON Study: Bevacizumab and Chemotherapy for Operable NSCLC

NCT00130780
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Pre-surgical Treatment with Bevacizumab plus Chemotherapy, Pre-Surgical Docetaxel and Cisplatin and Adjuvant Bevacizumab
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 25, 2016 · Synced Oct 25, 2026, 9:41 AM EDT
Completed Phase 1 Interventional

First-in-human Study of BAY2287411 Injection, a Thorium-227 Labeled Antibody-chelator Conjugate, in Patients With Tumors Known to Express Mesothelin

NCT03507452
View directory record Official record
Conditions
Advanced Recurrent Malignant Pleural Epithelioid Mesothelioma, Advanced Recurrent Malignant Peritoneal Epithelioid Mesothelioma, Advanced Recurrent Serous Ovarian Cancer, Advanced Pancreatic Ductal Adenocarcinoma (Optional, Dose Expansion, Not Initiated)
Interventions
BAY2287411
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
2
States / cities
Bethesda, Maryland • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 20, 2023 · Synced Oct 25, 2026, 9:41 AM EDT
Terminated Phase 1 Interventional

Erlotinib and Radiation Therapy Plus Combination Chemotherapy in Treating Patients With Inoperable Stage III Non-Small Cell Lung Cancer

NCT00042835
View directory record Official record
Conditions
Adenocarcinoma of the Lung, Bronchoalveolar Cell Lung Cancer, Large Cell Lung Cancer, Squamous Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer
Interventions
cisplatin, etoposide, erlotinib hydrochloride, radiation therapy, docetaxel, paclitaxel, carboplatin, laboratory biomarker analysis
Drug · Radiation · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 1, 2013 · Synced Oct 25, 2026, 9:41 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

KanSurvive: Testing a Model for Improving Cancer Survivorship Care in Rural Practice

NCT04763824
View directory record Official record
Conditions
Breast Cancer, Colorectal Cancer, Lung Cancer, Prostate Cancer
Interventions
KanSurvive ECHO and Practice Facilitation
Other
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Westwood, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 14, 2026 · Synced Oct 25, 2026, 9:41 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HH2710 in Patient With Advanced Tumors

NCT04198818
View directory record Official record
Conditions
Advanced Tumors, Melanoma, Non-Small-Cell Lung Cancer, Erdheim-Chester Disease, Other RAS/RAF/MEK/ERK Mutated Tumors
Interventions
HH2710
Drug
Lead sponsor
Haihe Biopharma Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
2
States / cities
Lafayette, Indiana • Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 19, 2024 · Synced Oct 25, 2026, 9:41 AM EDT
Completed Not applicable Interventional Results available

Facilitating Communication Study

NCT03721952
View directory record Official record
Conditions
Chronic Disease, Neoplasm Metastasis, Lung Neoplasm, Pulmonary Disease, Chronic Obstructive, Heart Failure, Congestive, Liver Cirrhosis, Kidney Failure, Chronic, Multiple Organ Failure, Health Care Quality, Access, and Evaluation, Intensive Care Units, Palliative Care, Health Services, Palliative Care, Patient Care, Lung Diseases, Cerebrovascular Disorders, Brain Injuries
Interventions
Facilitator-Based Intervention
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
977 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
3
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 7, 2025 · Synced Oct 25, 2026, 9:41 AM EDT
Terminated Phase 1 Interventional

Cediranib Maleate and Whole Brain Radiation Therapy in Patients With Brain Metastases From Non-Small Cell Lung Cancer

NCT00937482
View directory record Official record
Conditions
Male Breast Cancer, Stage IV Breast Cancer, Stage IV Melanoma, Stage IV Non-small Cell Lung Cancer, Stage IV Renal Cell Cancer, Stage IVA Colon Cancer, Stage IVA Rectal Cancer, Stage IVB Colon Cancer, Stage IVB Rectal Cancer, Tumors Metastatic to Brain
Interventions
cediranib maleate, whole-brain radiation therapy
Drug · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 8, 2013 · Synced Oct 25, 2026, 9:41 AM EDT
Completed Phase 3 Interventional Results available

Bintrafusp Alfa Program Rollover Study

NCT05061823
View directory record Official record
Conditions
Lung Cancer, Cancer
Interventions
Bintrafusp alfa
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
2
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 2, 2026 · Synced Oct 25, 2026, 9:41 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Development of a Clinical Trial Specific Question Prompt List

NCT00662324
View directory record Official record
Conditions
Breast Cancer, Lung Cancer, Prostate Cancer
Interventions
focus groups
Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 30, 2013 · Synced Oct 25, 2026, 9:41 AM EDT
Not yet recruiting Not applicable Interventional

Lumbar Punctures for the Detection of ctDNA in the Cerebrospinal Fluid of Patients With Stage III and IV Non-Small Cell Lung Cancer

NCT06816979
View directory record Official record
Conditions
Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
Interventions
Biospecimen Collection, Lumbar Puncture, Magnetic Resonance Imaging
Procedure · Device
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
Not listed
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Oct 25, 2026, 9:41 AM EDT
Terminated Phase 1Phase 2 Interventional

A Study of Nimotuzumab in Combination With External Radiotherapy in Non-Small Cell Lung Cancer

NCT00369447
View directory record Official record
Conditions
Non-small-cell Lung Cancer
Interventions
External radiotherapy, nimotuzumab
Procedure · Biological
Lead sponsor
YM BioSciences
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
New Port Richey, Florida
Source: ClinicalTrials.gov public record
Updated Jul 1, 2011 · Synced Oct 25, 2026, 9:41 AM EDT
Completed Phase 1Phase 2 Interventional

A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens

NCT03953235
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, Colorectal Cancer, Pancreatic Cancer, Solid Tumor, Shared Neoantigen-Positive Solid Tumors
Interventions
GRT-C903, GRT-R904, nivolumab, ipilimumab
Biological
Lead sponsor
Gritstone bio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
12
States / cities
Phoenix, Arizona • Santa Monica, California • Jacksonville, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2023 · Synced Oct 25, 2026, 9:41 AM EDT
Terminated Phase 1 Interventional

Phase Ib Study of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Non-small Lung Cancer (NSCLC) With Dual Immune Checkpoint Inhibition

NCT03275597
View directory record Official record
Conditions
Non-small Cell Lung Cancer, Non-small Cell Lung Cancer Stage IV
Interventions
Durvalumab, Tremelimumab, Stereotactic Body Radiotherapy
Drug · Radiation
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 15, 2023 · Synced Oct 25, 2026, 9:41 AM EDT
Completed Phase 1 Interventional

Optimization of Smoking Cessation Strategies Concurrent With Treatment of Tobacco Related Malignancies

NCT02048917
View directory record Official record
Conditions
Lung Cancer, Head and Neck Cancer
Interventions
High Intensity Counseling + Long Acting NRT + PRN NRT, High Intensity Counseling + bupropion + PRN NRT, High Intensity Counseling + varenicline + PRN NRT, High Intensity Counseling + Long Acting NRT, High Intensity Counseling + bupropion, High Intensity Counseling + varenicline, Low Intensity Counseling + Long Acting NRT + PRN NRT, Low Intensity Counseling + bupropion + PRN NRT, Low Intensity Counseling + varenicline + PRN NRT, Low Intensity Counseling + Long Acting NRT, Low Intensity Counseling + bupropion, Low Intensity Counseling + varenicline
Drug
Lead sponsor
University of Kentucky
Other
Eligibility
18 Years and older
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
10
States / cities
Ashland, Kentucky • Elizabethtown, Kentucky • Hazard, Kentucky + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2020 · Synced Oct 25, 2026, 9:41 AM EDT
Completed Phase 2 Interventional Results available

Induction Gemcitabine & Carboplatin Followed by Paclitaxel & Carboplatin +XRT in NSCLC

NCT00226590
View directory record Official record
Conditions
Lung Cancer
Interventions
Gemcitabine, Carboplatin, Paclitaxel, Radiation
Drug · Procedure
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Mar 23, 2017 · Synced Oct 25, 2026, 9:41 AM EDT
Completed Phase 2 Interventional

Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer

NCT00416650
View directory record Official record
Conditions
Lung Cancer
Interventions
erlotinib hydrochloride
Drug
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2013
U.S. locations
4
States / cities
Chicago, Illinois • New York, New York • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2013 · Synced Oct 25, 2026, 9:41 AM EDT